SDHB and neoplasm: Although sunitinib/everolimus combination treatment seemed to be less promising than other combining strategies in vitro, Ayala-Ramirez et al. reported the case of a 20-year-old woman with a SDHB-mutated tumor who experienced a long-term disease control under the mTORC1 inhibitor sirolimus in combination with sunitinib [11,73,78].